Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Morphine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.96 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.96 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.96 |
| ▸ | MRGPRX2 | Q96LB1 | 4/20 | 0.96 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.96 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morphine SCHEMBL7987114 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13154676 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13076870 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL8049464 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13696339 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL24599520 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL2997 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL10820235 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL5183254 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| Morphine SCHEMBL13695381 | 0.98 | OPRD1 (1.00) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-20230414604-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2023-12-28 | — | — | US | claimed |
| US-20200345720-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2020-11-05 | — | — | US | claimed |
| US-20190167665-A1 | MORPHINE FORMULATIONS | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2019-06-06 | — | — | US | claimed |
| US-20160175297-A1 | Morphine Formulations | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2016-06-23 | — | — | US | claimed |
| EP-2968132-A1 | INJECTABLE MORPHINE FORMULATIONS | Becton Dickinson France S.A.S (FR) | 2016-01-20 | — | — | EP | claimed |
| US-9192608-B2 | Morphine formulations | BECTON DICKINSON FRANCE S.A.S. (FR) | 2015-11-24 | — | — | US | claimed |
| US-20150246036-A1 | Morphine Formulations | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2015-09-03 | — | — | US | claimed |
| WO-2014153099-A2 | METHOD FOR USING EXHALED BREATH TO DETERMINE THE PRESENCE OF DRUG | Pulmonary Analytics (US) | 2014-09-25 | — | — | WO | claimed |
| US-20140288454-A1 | Method For Using Exhaled Breath to Determine the Presence of Drug | Pulmonary Analytics (US) | 2014-09-25 | — | — | US | claimed |
| WO-2014140095-A1 | INJECTABLE MORPHINE FORMULATIONS | BECTON DICKINSON FRANCE S.A.S. (FR) | 2014-09-18 | — | — | WO | claimed |
| EP-0767663-B1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORP (US) | 2002-04-03 | — | — | EP | claimed |
| EP-0767663-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1997-04-16 | — | — | EP | claimed |
| US-5593695-A | Morphine therapy | ALZA CORPORATION (US) | 1997-01-14 | — | — | US | claimed |
| WO-1996000066-A1 | COMPOSITION COMPRISING MORPHINE, POLYPYRROLIDONE AND A POLYALKYLENEOXIDE | ALZA CORPORATION (US) | 1996-01-04 | — | — | WO | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| WO-1998031358-A1 | d-METHADONE, A NONOPIOID ANALGESIC | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-07-23 | — | — | WO | disclosed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200345720-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20190167665-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRM1 4810/4885OPRD1 4518/4885OPRK1 2862/4885 |
| US-20230414604-A1 | MORPHINE FORMULATIONS | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20150246036-A1 | Morphine Formulations | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
| US-20160175297-A1 | Morphine Formulations | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885OPRD1 3/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.